Supplementary Figure S5 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Mark Yarchoan,John D. Powderly,Bruno R. Bastos,Thomas B. Karasic, Oxana V. Crysler,Pamela N. Munster,Meredith A. McKean,Leisha A. Emens, Yvonne M. Saenger,Yasser Ged,Robert Stagg, Steven Smith,Chan C. Whiting,Anne Moon,Peppi Prasit,Yonchu Jenkins,Nathan Standifer,Thomas W. Dubensky,Sam H. Whiting,Susanna V. Ulahannan

crossref（2024）

引用 0|浏览5

暂无评分

摘要

Elevated circulating free fatty acids (FFA) at days 57 and 85 in PR patients. Log2-fold changes in baseline normalized FFA in patients enrolled in Part 2. Samples were collected prior to TPST-1120 dose administration on day 1 of each 28-day cycle. Blue symbols: PD/SD patients; Red symbols: PR patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要